TEVOGEN BIO SPECIALTY CARE REPORTS TOP-LINE REVENUE FORECAST OF NEARLY $1 BILLION IN LAUNCH YEAR AND CUMULATIVE 5-YEAR ESTIMATE BETWEEN $18 BILLION AND $22 BILLION

Reuters · 10/21 19:58

Please log in to view news